Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

R. Langlois, Michel; John Chapman, M.; M. Cobbaert, Christa; Mora, Samia; T. Remaley, Alan; Ros, Emilio; F. Watts, Gerald; Borén, Jan; Baum, H; Bruckert, Éric; L. Catapano, Alberico; Descamps, Olivier; von Eckardstein, Arnold; R. Kamstrup, Pia; Kolovou, Genovefa; Kronenberg, Florian; Langsted, Anne; Pulkki, Kari; Rifai, Nader; Sypniewska, Grażyna; Wiklund, Olov; G. Nordestgaard, Børge

doi:10.1373/clinchem.2018.287037

Public

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM

Published in Clinical Chemistry • May 14, 2018

Authors:

Michel R. Langlois

M. John Chapman

Christa M. Cobbaert

Abstract

Abstract BACKGROUND The European Atherosclerosis Society–European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to optimize atherogenic lipoprotein quantification for cardiovascular risk management. CONTENT We critically examined LDL cholest...

Subject

Ldl cholesterol

Statement (logic)

Cholesterol

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!